Barclays
NMTC icon

Barclays’s NeuroOne Medical Technologies NMTC Stock Holding History

Barclays’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231 Buy
+76
New +$310 ﹤0.01% 5094

Other funds holding NMTC

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Barclays's NMTC Position: Q2 2026 in Review

Barclays opened a new position in NeuroOne Medical Technologies (NMTC) in Q2 2026: 76 shares worth $231. The stake represents ﹤0.01% of the portfolio and ranks #5094 among its holdings.

27 funds tracked by Wall St. Rank hold NMTC as of Q2 2026.

  • Barclays held 76 shares of NeuroOne Medical Technologies worth $231 as of Q2 2026.
  • NeuroOne Medical Technologies was a new Barclays position in Q2 2026.
  • NeuroOne Medical Technologies made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5094 holding.
  • 27 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.